Success Metrics

Clinical Success Rate
97.2%

Based on 104 completed trials

Completion Rate
97%(104/107)
Active Trials
2(2%)
Results Posted
10%(10 trials)
Terminated
3(2%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_1
7
6%
Ph phase_2
11
9%
Ph phase_3
66
54%
Ph phase_4
35
28%

Phase Distribution

7

Early Stage

11

Mid Stage

101

Late Stage

Phase Distribution120 total trials
Phase 1Safety & dosage
7(5.8%)
Phase 2Efficacy & side effects
11(9.2%)
Phase 3Large-scale testing
66(55.0%)
Phase 4Post-market surveillance
35(29.2%)
N/ANon-phased studies
1(0.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.3%

104 of 108 finished

Non-Completion Rate

3.7%

4 ended early

Currently Active

2

trials recruiting

Total Trials

123

all time

Status Distribution
Active(2)
Completed(104)
Terminated(4)
Other(13)

Detailed Status

Completed104
unknown13
Terminated3
Withdrawn1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
123
Active
2
Success Rate
97.2%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (5.8%)
Phase 211 (9.2%)
Phase 366 (55.0%)
Phase 435 (29.2%)
N/A1 (0.8%)

Trials by Status

completed10485%
withdrawn11%
recruiting11%
terminated32%
unknown1311%
active_not_recruiting11%

Recent Activity

2 active trials
Showing 5 of 123
active_not_recruitingphase_4

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

NCT05366868
completedphase_2

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

NCT04300790
unknownphase_3

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period

NCT02849899
unknown

Cognitive Protective Effect of Newer Antidiabetic Drugs

NCT05347459
unknown

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

NCT05429554
View all 123 trials

Clinical Trials (123)

Showing 20 of 123 trialsScroll for more
NCT05366868Phase 4

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Active Not Recruiting
NCT04300790Phase 2

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Completed
NCT02849899Phase 3

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period

Unknown
NCT05347459

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown
NCT05429554

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

Unknown
NCT05359432Phase 4

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Completed
NCT05102149Phase 3

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Unknown
NCT00860288Phase 2

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Completed
NCT00382096Phase 3

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Completed
NCT04654676Phase 4

DPP4 Inhibitor on Glycemic Variability

Completed
NCT00633997Phase 1

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Terminated
NCT00102466Phase 3

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Completed
NCT00646542Phase 3

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Completed
NCT00818571Phase 1

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Completed
NCT00099853Phase 3

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Completed
NCT00616811Phase 3

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Completed
NCT01159249Phase 3

Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Completed
NCT00106340Phase 3

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Completed
NCT00765830Phase 3

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Completed
NCT00894868Phase 4

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Completed

Drug Details

Intervention Type
DRUG
Total Trials
123